CDK1 drives SOX9-mediated chemotherapeutic resistance in gastric cancer.

ABSTRACT:

Background

Gastric carcinoma ranks as the fifth most common cause of cancer-related mortality globally. Chemoresistance remains a critical barrier to treatment efficacy, driving poor survival outcomes in gastric cancer patients. Cyclin-dependent kinase 1 (CDK1) is overexpressed in several malignancies. SOX9 transcription factor plays critical roles in gastric tumorigenesis and therapeutic resistance. This study identifies a CDK1-SOX9-BCL-xL signaling axis as an important mediator of chemoresistance in gastric cancer.

Methods

Bioinformatics and computational approaches were used for analysis of human and mouse public and local data sets. Chromatin immunoprecipitation (ChIP), western blotting, quantitative PCR (qPCR), immunofluorescence, and immunohistochemistry assays were ap

SUBMITTER: Al-Mathkour M 

PROVIDER: S-EPMC12506374 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature